InvVax Overview
- Year Founded
-
2012
- Status
-
Private
- Employees
-
4
- Latest Deal Type
-
2ndary - Private
- Investors
-
7
InvVax General Information
Description
Developer of a universal influenza vaccine designed to provide broad and lasting protection against all flu strains. The company targets invariant regions of the flu virus genome to prevent pandemics by enhancing immune responses to viral diseases, enabling global populations to benefit from a vaccine that prevents viral mutation and reduces the risk of seasonal mismatches.
Contact Information
Website
www.inv-vax.comCorporate Office
- 370 Amapola Avenue
- Suite 100
- Torrance, CA 90501
- United States
Corporate Office
- 370 Amapola Avenue
- Suite 100
- Torrance, CA 90501
- United States
InvVax Timeline
InvVax Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 12. Secondary Transaction - Private | 01-Jan-2025 | Completed | Generating Revenue | |||
| 11. Accelerator/Incubator | 01-Jan-2025 | Completed | Generating Revenue | |||
| 10. Equity Crowdfunding | 01-Apr-2024 | Completed | Generating Revenue | |||
| 9. Accelerator/Incubator | 01-Mar-2022 | Completed | Generating Revenue | |||
| 8. Later Stage VC | 01-Jan-2021 | Completed | Generating Revenue | |||
| 7. Later Stage VC | 01-Sep-2019 | Completed | Generating Revenue | |||
| 6. Later Stage VC | 27-Nov-2018 | Completed | Generating Revenue | |||
| 5. Later Stage VC | 01-Jan-2018 | Completed | Generating Revenue | |||
| 4. Accelerator/Incubator | 01-Jan-2017 | $375K | Completed | Generating Revenue | ||
| 3. Later Stage VC | 01-Jan-2017 | $375K | Completed | Generating Revenue |
InvVax Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Seed-3 | ||||||||
| Seed-2 | ||||||||
| Seed | 1,136,268 | $0.000100 | 6% | $0.39 | $0.39 | 1x | $0.39 | 12.49% |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
InvVax Patents
InvVax Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2017386682-A1 | Influenza vaccines | Inactive | 28-Dec-2016 | ||
| CA-3048448-A1 | Influenza vaccines | Inactive | 28-Dec-2016 | ||
| EP-3562498-A1 | Influenza vaccines | Inactive | 28-Dec-2016 | ||
| EP-3562498-A4 | Influenza vaccines | Inactive | 28-Dec-2016 | ||
| US-11111277-B2 | Influenza vaccines | Active | 28-Dec-2016 | C07K14/005 |
InvVax Signals
InvVax Investors (7)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Pasadena Bio | Accelerator/Incubator | |||
| Angel (individual) | Minority | |||
| US National Science Foundation | Accelerator/Incubator | |||
| Evolution VC Partners | Venture Capital | Minority | ||
| Seeds San Diego | Venture Capital | Minority |
InvVax FAQs
-
When was InvVax founded?
InvVax was founded in 2012.
-
Where is InvVax headquartered?
InvVax is headquartered in Torrance, CA.
-
What is the size of InvVax?
InvVax has 4 total employees.
-
What industry is InvVax in?
InvVax’s primary industry is Drug Discovery.
-
Is InvVax a private or public company?
InvVax is a Private company.
-
What is InvVax’s current revenue?
The current revenue for InvVax is .
-
How much funding has InvVax raised over time?
InvVax has raised $2.5M.
-
Who are InvVax’s investors?
Pasadena Bio, , US National Science Foundation, Evolution VC Partners, and Seeds San Diego are 5 of 7 investors who have invested in InvVax.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process